Genfit SA
(NASDAQ : GNFT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -2.02%167.220.7%$966.81m
ABBVAbbVie, Inc. 0.80%142.071.9%$836.12m
PFEPfizer Inc. -3.27%48.320.9%$816.98m
LLYEli Lilly & Co. -0.95%301.721.1%$776.48m
MRKMerck & Co., Inc. -0.31%88.920.7%$771.89m
BMYBristol-Myers Squibb Co. -0.56%74.441.0%$667.52m
SIGASIGA Technologies, Inc. 8.65%24.880.0%$467.13m
AZNAstraZeneca Plc -1.79%64.661.0%$355.66m
ALNYAlnylam Pharmaceuticals, Inc. -1.19%229.248.2%$281.44m
GBTGlobal Blood Therapeutics, Inc. -0.38%66.595.6%$275.32m
GSKGSK Plc -6.67%35.750.3%$212.12m
HZNPHorizon Therapeutics Plc -1.91%67.115.4%$208.61m
NVONovo Nordisk A/S 1.16%108.760.1%$177.06m
NVSNovartis AG -2.00%85.690.2%$175.96m
CCXIChemoCentryx, Inc. -0.43%50.652.9%$174.92m

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.